Life Sciences & Chemistry

Start-up = challenge? Let’s tackle it together! 

Are you a founder in the field of life science and chemistry and on the lookout for financing? At HTGF, we not only offer you investment know-how, but also understand your specific needs and provide you with the right expertise to support your business ideas. We leverage our tailored network to help you achieve success.

Our Life Sciences & Chemistry team has the required start-up spirit! We have both entrepreneurial expertise and an understanding of science, medicine and practical applications. Having invested in over 200 life science and chemical companies since 2005, we know what really matters.

With our expertise and passion, we are at your side as a sparring partner from seed to exit – whether it be in the field of drug development and biotech, medtech and diagnostics, digital health, R&D tools or chemistry.

 Many steps must be taken to become a successful start-up

The right tools

We offer you the right tools to meet your individual challenges as a founder of a life sciences and chemical start-up:

We help you get started

  • Fast and flexible seed financing
  • Matching with co-investors from our international network
  • Communication on an equal footing
  • Inspiration and knowledge transfer

Let’s develop and grow together

  • Support in the acquisition of follow-up financing
  • Exchanges with founders and our partners from research, industry and SMEs
  • Close connection with cooperation partners

A shared path – from seed to exit

  • Support in finding the most suitable M&A advisors
  • Support in negotiations and due diligence
  • Assistance with company valuations and incentives
  • Transaction security from trade sale to IPO
  • Access to the HTGF network with many potential buyers

Who we are

What you can expect from us

  • From the very early stage to the exit, we support you as partners with our know-how and understanding of your needs.
  • We have an entrepreneurial spirit – many of us have founded our own companies and we have the necessary appetite for risk
  • We understand how financing works and can call on our network
  • We have backgrounds as scientists and know the pitfalls: manufacturing/CMC, regulatory affairs, market access, team growth, business development, etc.

The areas we invest in include:

  Pharma/biotech

  Medtech

  R&D tools

  Diagnostics

  Digital health

  Chemistry

Our Life Sciences & Chemistry Portfolio 

Let’s turn ideas into reality!

Societal challenges, such as diseases or advancing climate change, require innovative solutions. And this is why pioneering start-ups in the fields of life sciences and healthcare, chemistry, food and agricultural technology, and new materials are playing a crucial role.

Germany has the platform to continue launching successful high-tech start-ups:

  • Top-class research at universities and institutes
  • Close cooperation between industry and consumers
  • Transfer-enabling support

With your innovative start-up ideas, we can create sustainable and disruptive solutions together – what are we waiting for?

Looking to start a business? Contact our team here.

Is your pitch deck complete? Upload it here!

Topics that might interest you

Press
7. September 2022

faCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF

Proprietary intelligent polymer surface coating platform enables development of first-in-class lab materials for modern cell culture applications Closing of seed round completed raising €3.7 million from SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft and Chemovator.faCellitate has developed an intelligent and ultra-low attachment polymer surface coating platform. The first launched product thereof is targeting 3D cell culture, enabling
 
Press
1. September 2022

C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring

C-mo Medical Solutions is an award-winning start-up that is unravelling the potential of assessing cough towards improved diagnosis, treatment courses and disease management. The company has now raised 4.1€Mn in a seed round led by Boehringer Ingelheim Venture Fund. This investment will allow the company to bring its innovative cough-monitoring technology to the market. Lisbon, 1 September 2022 – C-mo Medical Solutions has announced today the closing of a 4.1€Mn seed investment roun
 
Press
22. June 2022

TechVision Fonds I and High-Tech Gründerfonds invest in textile recycling startup EEDEN

Textile recycling rethought: Innovative process enables upcycling of old clothing Aachen, 22 June 2022 – TechVision Fonds I, together with High-Tech Gründerfonds (HTGF) and a business angel, are the first investors to invest in EEDEN. The startup from Moenchengladbach, Germany has developed an innovative process for the sustainable and environmentally friendly recycling of clothing and other textile products. With the financing, EEDEN plans to further expand their R&D-activities and
 
Press
7. June 2022

Invasight closes CHF 4.5 million oversubscribed seed round

The funds will accelerate the development of targeted therapies with superior safety profile for patients with invasive cancers. Zurich, Switzerland, 7 June 2022 – Invasight AG, a Swiss pre-clinical stage biotech company with a mission to develop their breakthrough targeted therapies for invasive cancers, announced the closing of a CHF 4.5 million seed round. The seed financing round was led by OCCIDENT and co-led by JFG Life Sciences Foundation, with participation from Verve Ventures,
 
Press
3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of
 
Blog
18. May 2022

GWA Hygiene and Dräger: From collaboration to investment

How does a company specialized in medical and safety technology with a more than 130-year history end up getting together with a six-year-old start-up? Common goals, collaboration on an equal footing and good partners are key aspects in this regard. That is at least according to Jens Altmann, President Business Unit Data Business at Dräger, and Tobias Gebhardt, CEO at GWA Hygiene. Dräger, a global corporation, recently invested in High-Tech Gründerfonds (HTGF) portfolio company GWA Hygien